TTrialPathMatch Me to Trials
← Back to trials
RecruitingPancreatic CancerPancreatic Cancer MetastaticPDAC

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Eligible age

18+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

Sponsor: Revolution Medicines, Inc.

You may qualify if…

  • ✓ At least 18 years old and has provided informed consent.
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • ✓ Histologically or cytologically confirmed pancreatic adenocarcinoma, including adenosquamous carcinoma, not previously treated in the locally advanced unresectable or metastatic setting.
  • ✓ No prior treatment in the locally advanced unresectable or metastatic setting
  • ✓ Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.
  • ✓ Documented KRAS G12D mutation status.
  • ✓ Measurable disease per RECIST v1.1.
  • ✓ Adequate organ function (bone marrow, liver, kidney, coagulation).

You may not qualify if…

  • ✕ Mutation status with known driver mutations for which there are approved targeted therapies.
  • ✕ Acinar cell carcinoma, pancreatic neuroendocrine tumors, tumors involving islet cells or islet cell neoplasms, and other non-adenocarcinoma pancreatic malignancies.
  • ✕ Tumors determined to originate from non-pancreatic primary sites.
  • ✕ Prior treatment with MAPK-pathway targeted therapy or administration of RAS-targeted vaccine in the metastatic setting.
  • ✕ Active or known history of untreated central nervous system metastatic or leptomeningeal disease.
  • ✕ Any conditions that may affect the ability to take or absorb study drug.
  • ✕ Major surgery within 28 days prior to randomization.
  • ✕ Patient is unable or unwilling to comply with protocol-required study visits or procedures.

Where it's recruiting

Arizona

Phoenix · Scottsdale

Florida

Jacksonville · Tampa

Minnesota

Rochester

Rhode Island

Providence

Source: ClinicalTrials.gov · NCT07805954 · last updated 2026-11-06

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Ge · TrialPath